Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1

Shengqing Gu, Wayne W. Chan, Golam Mohi, Joel Rosenbaum, Azin Sayad, Zhibin Lu, Carl Virtanen, Shaoguang Li, Benjamin G. Neel, Richard A. Van Etten

Blood (2016) 127 (14): 1803–1813.

https://doi.org/10.1182/blood-2015-06-653006

Published: 2016

Includes: Supplemental data

Journal Articles

Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL

M. Golam Mohi, PhD, Wayne W. Chan, BA, Shaoguang Li, MD, PhD, Benjamin Neel, MD, PhD, Richard A. Van Etten, MD, PhD

Blood (2008) 112 (11): 570.

https://doi.org/10.1182/blood.V112.11.570.570

Published: 2008

Journal Articles

Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I

Richard A. Van Etten, MD, PhD, Wayne W. Chan, BA, Virginia M. Zaleskas, MD, Christoph Walz, MD, Peter Evangelista, BA, Katherine Lazarides, BS, Monica Betancur, MS, Scott Wise, MS, Peter A. Petillo, PhD, Daniel L. Flynn, PhD

Blood (2008) 112 (11): 576.

https://doi.org/10.1182/blood.V112.11.576.576

Published: 2008

Journal Articles

A Selective and Potent Oral Inhibitor of the JAK2 Tyrosine Kinase Reverses Polycythemia and Leukocytosis Induced by JAK2 V617F in a Mouse Model.

Virginia M. Zaleskas, MD, Wayne W. Chan, BS, Peter Evangelista, BS, Katherine Lazarides, BS, Rajesh Chopra, MD, Michael Zinda, PhD, Dennis Huszar, PhD, Richard A. Van Etten, MD PhD

Blood (2007) 110 (11): 557.

https://doi.org/10.1182/blood.V110.11.557.557

Published: 2007

Journal Articles

DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.

Richard A. Van Etten, MD, PhD, Wayne W. Chan, BS, Virginia M. Zaleskas, MD, PhD, Peter Evangelista, BS, Katherine Lazarides, BS, Cong Peng, PhD, Shaoguang Li, MD, PhD, Scott C. Wise, PhD, Peter Petillo, PhD, Daniel L. Flynn, PhD

Blood (2007) 110 (11): 463.

https://doi.org/10.1182/blood.V110.11.463.463

Published: 2007

NARROW

Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1

Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL

Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I

A Selective and Potent Oral Inhibitor of the JAK2 Tyrosine Kinase Reverses Polycythemia and Leukocytosis Induced by JAK2 V617F in a Mouse Model.

DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.

Email alerts

ASH Publications

American Society of Hematology

Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1

Distinct Gab2-Mediated Signaling Pathways Are Essential for Myeloid or Lymphoid Transformation and Leukemogenesis by BCR-ABL

Switch Pocket Inhibitors of the ABL Tyrosine Kinase: Distinct Kinome Inhibition Profiles and in Vivo Efficacy in Mouse Models of CML and B-Lymphoblastic Leukemia Induced by BCR-ABL T315I

A Selective and Potent Oral Inhibitor of the JAK2 Tyrosine Kinase Reverses Polycythemia and Leukocytosis Induced by JAK2 V617F in a Mouse Model.

DCC-2036: A Novel Switch Pocket Inhibitor of ABL Tyrosine Kinase with Therapeutic Efficacy Against BCR-ABL T315I In Vitro and in a CML Mouse Model.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only